Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 3/20 | 0.34 |
| ▸ | CTSS | P25774 | 8/20 | 0.32 |
| ▸ | TDO2 | P48775 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | XDH | P47989 | 1/20 | 0.30 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.30 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.30 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.30 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.30 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.30 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.30 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.30 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formic Acid SCHEMBL25240514 | 0.96 | PIK3CA (0.33) | PIK3CACTSSXDHPRKAB2PRKAG1 | |
| Formic Acid SCHEMBL30467680 | 0.96 | PIK3CA (0.33) | PIK3CACTSSXDHPRKAB2PRKAG1 | |
| SCHEMBL24252357 | 0.90 | PDE10A (0.36) | PIK3CAPDE10AC5AR1 | |
| SCHEMBL25240512 | 0.90 | PIK3CA (0.33) | PIK3CA | |
| Formic Acid SCHEMBL30467714 | 0.86 | TRPC6 (0.34) | PIK3CAPDE10AC5AR1 | |
| Formic Acid SCHEMBL25244072 | 0.86 | TRPC6 (0.34) | PIK3CAPDE10AC5AR1 | |
| SCHEMBL24252633 | 0.85 | CNR2 (0.36) | PIK3CACTSSTDO2PDE10APRKAB2 | |
| SCHEMBL26771314 | 0.83 | PDE10A (0.36) | PIK3CAPDE10AC5AR1 | |
| SCHEMBL24252661 | 0.81 | TBK1 (0.37) | PIK3CA | |
| SCHEMBL24252495 | 0.80 | CNR2 (0.38) | PIK3CATDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20220048930-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | ANNEXON, INC. | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220048930-A1 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | CFB, CFH, C9 | PIK3CA 2052/4885CTSS 594/4885TDO2 4128/4885 |
| US-11814404-B2 | Inhibitors of complement factors and uses thereof | CFB, CFH, C9 | PIK3CA 2052/4885CTSS 594/4885TDO2 4128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.